Lundbeck-backed pruritus therapy developer Trevi Therapeutics raised $55m when it floated, but had to price its shares significantly below its range.

Trevi Therapeutics, a US-based pruritus treatment developer backed by pharmaceutical firm Lundbeck, has floated in a $55m initial public offering on the Nasdaq Global Market. The company issued 5.5 million shares priced at $10 each, a drop from the IPO’s $14 to $16 range, and they closed at $8.27 on Friday. Venture capital firm and…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.